Article
CTLA4 blockade broadens the peripheral T-cell receptor repertoire.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 May 2014
Robert Lidia, Tsoi Jennifer, Wang Xiaoyan, Emerson Ryan, Homet Blanca, Chodon Thinle, Mok Stephen, Huang Rong Rong, Cochran Alistair J, Comin-Anduix Begoña, Koya Richard C, Graeber Thomas G, Robins Harlan, Ribas Antoni
Abstract excerpt
PURPOSE: To evaluate the immunomodulatory effects of cytotoxic T-lymphocyte-associated protein 4 (CTLA4) blockade with tremelimumab in peripheral blood mononuclear cells (PBMC). EXPERIMENTAL DESIGN: We used next-generation sequencing to study the complementarity-determining region 3 (CDR3) from the rearranged T-cell receptor (TCR) variable beta (V-beta) in PBMCs of 21 patients, at baseline and 30 to 60 days after...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.